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Abstract. To clarify the role of poly(ADP-ribose)poly-
merase-1 ( PARP-1) in myocardial ischemia-reperfusion 
injury, we explored some effects of PJ34, a highly specific 
inhibitor of this enzyme, in hypoxic-reoxygenated (HR) 
H9c2 cardiomyoblasts. Compared to the control, HR cells 
showed signs of oxidative stress, marked PARP-1 activa-
tion, NAD+ and ATP depletion and impaired mitochon-
drial activity. HR cardiomyoblasts were affected by both 
necrosis and apoptosis, the latter involving the nuclear 
translocation of apoptosis-inducing factor. In HR cardio-
myoblasts treated with PJ34, oxidative stress and PARP-1 
activity were decreased, and NAD+ and ATP depletion, 
as well as mitochondrial impairment, were attenuated. 
Above all, PJ34 treatment improved the survival of HR 
cells; not only was necrosis significantly diminished, but 
apoptosis was also reduced and shifted from a caspase-in-
dependent to a caspase-dependent pathway. These results 
suggest that PARP-1 modulation by a selective inhibitor 
such as PJ34 may represent a promising approach to limit 
myocardial damage due to post-ischemic reperfusion.
Keywords. Cardiomyoblasts, PARP, hypoxia-reoxygenation, apoptosis, necrosis.
Introduction
Reactive oxygen species (ROS) are believed to play a key 
role in the myocardial ischemia-reperfusion (IR) injury. 
In this condition, ROS production, which may initiate 
during the ischemic phase but is exacerbated by reperfu-
sion, often overcomes the antioxidant defenses and in-
duces oxidative stress [1]. Similar effects are observed in 
hypoxic-reoxygenated (HR) cells and these may, there-
fore, represent a suitable experimental model for studies 
about the cardiac damages due to post-ischemic reperfu-
sion [2, 3].
Myocardial cell death in IR is mediated mainly by necro-
sis [4], but recent evidence suggests that cardiomyocyte 
apoptosis could also play a significant role in these condi-
tions [5]. A mechanism that is involved in both myocyte 
necrosis and apoptosis induced by ischemia-reperfusion 
is based on the oxidative stress-induced activation of the 
nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-
1), whose activity consists in the transfer of ADP-ribose 
units from oxidized nicotinamide dinucleotide (NAD+) to 
nuclear proteins [6, 7].
The covalent modification of proteins by poly(ADP-
ribosyl)ation is an immediate and dramatic biochemical 
response to DNA damage induced by oxidation and other 
agents such as alkylation, and ionizing radiation. Binding 
to damaged DNA potently activates the enzymatic activ-
ity of PARP-1, which can, therefore, function as a DNA 
damage sensor. PARP-1 has been implicated in multiple 
DNA repair pathways, including those involved in the re-
pair of single-strand breaks (SSB), double-strand breaks 
(DSB), and base excision (BE) [8]. As expected, PARP-1 
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physically and functionally interacts with various proteins 
involved in these pathways and may recruit the repair pro-
teins to the sites of DNA damage (e.g. XRCC-1 in BE, 
DNA-dependent protein kinase in DSB repair) [9].
It is generally accepted that PARP-1 activation results in 
NAD+ and ATP depletion; hence, cell dysfunction and 
cell death occur mainly via the necrotic route. However, 
in addition to this well-established mechanism, recent 
studies conducted on various cell types have suggested a 
potential role of PARP-1 in apoptosis through the trans-
location of apoptosis-inducing factor (AIF), from the mi-
tochondria to the nucleus [10].
Based on this background, the aim of the present study 
was to investigate if the rate of PARP-1 activation could 
affect the extent and the mode of death of hypoxic (H) 
and HR cardiac cells. Necrosis and apoptosis were evalu-
ated in H and HR cardiomyoblasts in the absence and 
in the presence of PJ34, a potent and specific PARP-1 
inhibitor.
Materials and methods
Chemicals and reagents. All chemicals were of reagent 
grade and were obtained from Sigma (Milan, Italy) un-
less otherwise indicated; PJ34 was from Calbiochem (La 
Jolla, CA, USA).
Cell cultures. Rat heart myoblasts [line H9c2 (2-1), 
no. 88092904; European Collection of Cell Cultures, 
ECACC] were plated at a density of 5 × 105/100-mm 
plate and cultured at 37 °C in a 5% CO2 humidified atmo-
sphere in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 10% heat-inactivated fetal bovine se-
rum (FBS), 1% penicillin, 1% streptomycin and 1% L-
glutamine. Cells were passaged regularly and subcultured 
to ∼ 90% confluence before experimental procedures.
Hypoxia/reoxygenation treatment protocol. Hypoxia 
was achieved using a modular incubator chamber (Bil-
lups-Rothenberg Inc., CA, USA) gassed with 95% N2 , 
5% CO2. A flow meter was used to measure the quantity 
of gas mixture introduced into the chamber (25 l/min) 
according to Namiki et al. [11]. After incubating in hy-
poxic conditions for 6 h, the cells were reoxygenated 
by immediate replacement of fresh culture medium and 
were returned to a normoxic environment at 37 °C for 
120 min. Cell treatment was started at the moment of re-
oxygenation by adding PJ34 (0.5 µM final concentration) 
[12]. Normoxic control H9c2 cells with and without PJ34 
treatment were cultured concomitantly to check possible 
toxic effects of this compound. No significant differences 
in lactate dehydrogenase (LDH) release or in cell viabil-
ity was observed when comparing the untreated with the 
treated cells (data not shown).
Preparation of cell homogenates and isolation of 
nuclear, cytosolic and mitochondrial fractions. H9c2 
cells (1 × 106) were washed twice with phosphate buff-
ered saline ( pBS), trypsinized, collected by centrifuga-
tion and then resuspended in 120 µl lysis buffer [1% Tri-
ton X-100, 20 mM Tris-HCl pH 8, 137 mM NaCl, 10% 
(v/v) glycerol, 2 mM EDTA and 6 M urea supplemented 
with 0.2 mM PMSF, as well as 10 µg/ml leupeptin and 
aprotinin]. Except for particular assays to obtain cell ho-
mogenate (see below), samples, after three freeze-thaw 
cycles, were sonicated twice in ice for 5 s and centrifuged 
at 14 000 g for 10 min at 4 °C. The supernatant was then 
collected. Nuclear, cytosolic and mitochondrial fractions 
were achieved using a cytosol/mitochondria fractionation 
kit according to the manufacturer’s instructions (Onco-
gene Research Products, San Diego, CA, USA). The pro-
tein concentration was determined in total homogenates 
and in subcellular fractions according to the BCA assay 
[13] with BSA as standard.
Assays for oxidative-stress markers: Lipid peroxida-
tion products, protein carbonyls, 8-hydroxy-2′-deoxy-
guanosine, total antioxidant capacity. These determina-
tions were all performed using total homogenate samples. 
Aliquots of 200 µl were used to assess the rate of lipid 
peroxidation by measuring malonaldehyde (MDA) and 
4-hydroxyalkenals (4-HNE) using a colorimetric method 
(LPO-586, Oxis International, Inc., OR, USA) based on 
the reaction of a chromogenic reagent, N-methyl-2-phe-
nylindole, with MDA or 4-HNE at 45 °C [14].
The protein carbonyl content was determined accord-
ing to the method of Levine et al. [15] after the removal 
of nucleic acids from the samples. Spectrophotometric 
measurement was performed at 375 nm considering 
22 000 M–1 cm–1 as the molar absorption coefficient.
The oxidative DNA adduct 8-hydroxy-2′-deoxyguanosine 
(8-OhdG) was measured after DNA extraction (Quan-
tum Prep AquaPure Genomic DNA kit; Bio-Rad, Rome, 
 Italy) and digestion (DNase I, Sigma, Milano, Italy) with 
a competitive enzyme-linked immunosorbent assay (8-
OHdG Check Assay by JAICA, Shizuoka, Japan). The 
absorbance of the chromogenic product was measured at 
450 nm and the results were calculated from a standard 
curve based on a 8-OHdG solution.
Total antioxidant capacity (TAC) was determined by a 
competition-based chemiluminescent assay (ABEL An-
tioxidant Test Kit, Knight Scientific Limited, Plymouth, 
UK) using the photoprotein Pholasin. The results were 
calculated from a standard curve based on the soluble an-
tioxidant L-ascorbic acid.
PARP-1 activity measurement. PARP-1 activity was 
assessed on nuclear extracts (5 µg protein) by an immu-
nodot blot for poly(ADP-ribosylated) proteins according 
to Affar et al. [16] using the highly specific LP 98-10 
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anti-poly(ADP-ribose) antibody (Alexis Biochemicals, 
Lausen, Switzerland). Image analysis of the dot blot was 
performed with Quantity One software (Bio-Rad Labora-
tories, Milan, Italy).
Another approach that was used in the present study to 
quantify PARP activity comprised an enzymatic assay 
(Universal Colorimetric PARP assay kit, Trevigen Inc, 
Helgerman Ct., Gaithersburg, MD, USA). This method 
measures the incorporation of biotinylated poly(ADP-ri-
bose) onto histone proteins in cell homogenates accord-
ing to manufacturer instructions. The amount of PARP-1 
activity, assayed on cellular samples (50 µg) was deter-
mined by comparison to a standard curve obtained with 
an high specific activity (HSA) PARP [13 793 U/mg: 
1 U is defined as the amount of PARP that incorporates 
100 pmol poly (ADP-ribose) from NAD into acid-insol-
uble form in 1 min at 22 °C].
Intracellular ROS measurement. This was performed 
using the ROS-sensitive fluorescent probe dichlorodihy-
drofluorescin diacetate (DCFH-DA; final concentration 
10 µM) as described previously [17]. Fluorescence was 
monitored on a Perkin Elmer LS55 Spectrofluorimeter 
with λ ex 488 nm and λ em 520 nm. The results were ex-
pressed as percent of DCF fluorescence relative to control 
cells.
MTT reduction and trypan blue exclusion cell viability 
assays.  3-(4 , 5-Dimethylthiazal-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) reduction ability was determined 
as an index of the metabolic viability, notably of the mi-
tochondrial function of our cardiomyoblasts using the 
method of Denizot [18]. The absorbance of solubilized 
MTT formazan products was measured at 570 nm and the 
results were expressed as percentages, assuming the ab-
sorbance of control cells as 100%.
For trypan blue staining, control, H and HR cells were 
gently harvested, and mixed with 0.4% trypan blue solu-
tion (Sigma). The resulting cell suspension was counted 
with a hemocytometer; non-viable cells are stained and 
viable cells exclude the stain. The percentage of viable 
cells in the H and HR groups was determined from cell 
counts in H and HR groups divided by cell counts of con-
trols. Thus, a reduction in the number of viable cells re-
flects decreased cell viability.
Determination of intracellular NAD+ and ATP levels. 
Cellular NAD+ levels were measured using a method 
based on its conversion to NADH by alcohol dehydro-
genase [19]. Cells were homogenized in 0.05 M potas-
sium phosphate buffer containing 0.1 M nicotinamide 
( pH 6.0), frozen rapidly, placed in a boiling water bath 
for 5 min, then cooled in an ice bath for 5 min. Samples 
were centrifuged for 10 min at 100 g at 4 °C. The super-
natant was then added to the reaction mixture containing 
glycylglycine buffer (0.065 M glycylglycine, 0.1 M nico-
tinamide, 0.5 M ethanol, pH 7.4), alcohol dehydrogenase, 
MTT and phenazine methosulfate (PMS).
ATP measurement was performed by a highly sensi-
tive bioluminescence assay (HS II, Roche Diagnostics, 
Mannheim, Germany), which is based on the ATP depen-
dency of the light emitting oxidation of luciferin cata-
lyzed by luciferase [20]. ATP measurement was achieved 
using a luminometer Lumat LB 9507 (EG & G Berthold). 
Both NAD+ and ATP levels were normalized to total pro-
tein content.
LDH measurement. LDH activity was assessed spectro-
phometrically in the culture medium and in adherent cells 
(to obtain total LDH content) using the LDH assay kit 
(Roche Diagnostics). LDH release was calculated as a 
percentage of total LDH content.
DNA fragmentation analysis. DNA fragmentation, ac-
counting for cell apoptosis, was determined using an immu-
nometric method (Cell Death Detection ELISAPLUS, Roche 
Diagnostics) according to the manufacturer’s instructions. 
DNA fragmentation was expressed as the enrichment of 
histone-associated mono- and oligonucleosomes released 
into the cytoplasm by measuring the absorption at 405 nm. 
The enrichment factor is considered to be proportional to 
the number of apoptotic cells present in the population. 
DNA fragmentation was also determined in the presence 
of the caspase inhibitor Z-VAD-fmk (100 µM) to assess 
the caspase dependence of this process.
Annexin V-FITC and PI labeling. FITC-conjugated An-
nexin V and PI labeling (Bender MedSystems, Vienna, 
Austria) were used to detect the externalization of phos-
phatidylserine during the apoptotic progression in cells 
exposed to hypoxia-reoxygenation [21]. After detach-
ment, cells were resuspended in binding buffer (10 mM 
HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) 
at a density of 5 × 105 cells/ml. Then, 25 µl/ml annexin 
V-FITC and 50 µl/ml PI were added. Within 30 min the 
labeled cells were determined using a FACSCalibur flow 
cytometer (Becton Dickinson, Milan, Italy).
PARP-1, caspase-3, cytochrome c and AIF assessment 
by Western blot. To assess the protein levels of PARP-1 
(cleaved form) equal amounts of nuclear fraction (40 µg) 
were diluted in Laemmli sample buffer and boiled at 
65 °C for 5 min. Proteins were separated on 10% SDS-
PAGE and were transferred to PVDF Hybond membrane 
(Millipore Corporation, Billerica, MA, USA). The mem-
brane was then incubated overnight at 4 °C with the highly 
specific (mouse) C2–10 anti-PARP-1 monoclonal antibody 
(Alexis Biochemicals). Equal protein amounts of total 
homogenate (40 µg for caspase-3), of cytosolic fractions 
(45 µg for cytochrome c) and of nuclear fractions (40 µg 
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for AIF) were diluted in Laemmli sample buffer, boiled 
for 5 min and separated by SDS-PAGE on 15% gels. Pro-
teins were transferred to PVDF Hybond membranes. The 
membranes were then incubated overnight at 4 °C with 
(rabbit) anti-caspase-3/CPP32 antibody (Biosource In-
ternational, CA, USA), (mouse) anti-cytochrome c (On-
cogene Research Products), and (rabbit) anti-AIF (Santa 
Cruz Biotechnology Inc, Santa Cruz, CA, USA). After 
washing, the membranes were incubated with peroxi-
dase-conjugated secondary antibodies for 1 h. The immu-
nolabeled bands were then detected using a SuperSignal 
West Dura ( pierce, Rockford, IL, USA) and quantified 
using the above-mentioned software for image analysis. 
Results were expressed as ratios between the densitom-
etry of the protein of interest and the densitometry of the 
loading control [β-tubulin (for homogenate and cytosol) 
and histone H1 (for nuclei)].
Statistical analysis. All data are expressed as mean 
± SEM. Comparisons between the different groups were 
performed by ANOVA followed by Bonferroni t-test. A 
p value of < 0.05 was accepted as statistically significant.
Results
ROS production and oxidative-stress markers in HR 
cells. Compared to the normoxic cells our HR cardio-
myoblasts exhibited a significant increase in ROS cellu-
lar levels. As indicated by the DCFH-DA fluorescence, 
this increase started at 5 min of reoxygenation and was 
prolonged until 90 min; at 120 min control levels were 
restored (Fig. 1). After 90 min of reoxygenation, the con-
centrations of MDA and 4-HNE (typical stable end prod-
ucts of the lipoperoxidative process), of protein carbonyls 
and of 8-OHdG also significantly increased, relative to 
the control value, in HR cells (Table 1). At this time, in 
correspondence with the presence of high levels of oxida-
tive-stress markers, the total antioxidant capacity, assayed 
as an index of antioxidant defenses, was significantly re-
duced. Hypoxia alone did not induce significant changes 
in ROS production, nor in the levels of oxidative-stress 
markers and of total antioxidant capacity with respect to 
control cells.
Although insufficient to completely restore the con-
ditions observed in the normoxic control cells, PJ34 
treatment produced significant changes in all the above 
parameters (Table 1). Compared to the corresponding 
untreated cells, HR cardiomyoblasts treated with PJ34 
exhibited a marked decrease in ROS production (Fig. 1) 
that was associated to reduced levels of all the consid-
ered oxidative-stress markers and to a higher total anti-
oxidant capacity.
PARP-1 activity, intracellular levels of NAD+ and ATP, 
and MTT reduction assay. PARP-1 activity, which is 
triggered by DNA strand breaks, and may therefore rep-
resent an indirect marker of free radical-induced genomic 
damage, was enhanced by hypoxia-reoxygenation. A sig-
nificant increase (about 80% above the control value) in 
the poly(ADP-ribosyl)ation of nuclear proteins was ob-
served after 90 min of reoxygenation (Fig. 2), parallel 
with the other findings that indicate the development of 
oxidative stress. In the enzymatic assay for PARP activ-
ity (Table 2) HR cells showed a threefold increase with 
respect to controls. PARP-1 activation was associated to 
a marked and significant reduction of mitochondrial ac-
tivity as judged by the MTT reduction test (Fig. 3A) with 
Figure 1. Time course of reactive oxygen species (ROS) generation 
in control (C), hypoxic (H), hypoxic-reoxygenated (HR) cardio-
myoblasts with and without PJ34. ROS production was measured 
at λ ex 488 nm and λ em 520 nm using the ROS-sensitive fluo-
rescent probe DCFH-DA (final concentration 10 µM). Each value 
represents the mean ± SEM of five different measures. * Signifi-
cant difference ( p < 0.05) from control, and ° significant difference 
( p < 0.05) from HR + PJ34.









Control 0.42 ± 0.04 3.62 ± 0.13 112.4  ± 4.21 1.14 ± 0.14
Hypoxia 0.47 ± 0.03 3.81 ± 0.17  98.3  ± 4.70 1.15 ± 0.18
HR 0.98 ± 0.07** 7.9  ± 0.25**  65.12 ± 5.41** 3.32 ± 0.17**
HR+PJ34 0.62 ± 0.03*† 5.15 ± 0.14**†  95.71 ± 3.51† 2.12 ± 0.15*†
a Oxidative-stress markers levels in control, hypoxic, hypoxic-reoxygenated (HR) cardiomyoblasts with and without PJ34. Values represent 
mean ± SEM of five independent experiments. **p < 0.001 vs C; *p < 0.05 vs C; †p < 0.001 vs HR
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respect to the control level and to a concomitant depletion 
of intracellular ATP and NAD+ pools (Fig. 3B, C).
In HR cardiomyoblasts treated with PJ34 PARP-1 activ-
ity (assessed by dot blot analysis and by enzymatic as-
say) was significantly lower than in the corresponding 
untreated cells, resulting only about 25% over the control 
level. Correspondingly, the impairment of mitochondrial 
activity (Fig. 3A) was significantly attenuated, as was the 
cellular depletion of both ATP and NAD+ (Fig. 3B, C).
Figure 2. Immunodot blot of ADP-ribosylation levels of PARP 
nuclear substrates. (a) Representative dot blot showing poly(ADP-
ribosylation) ( pAR) level of nuclear proteins in control (C), hy-
poxic (H) and hypoxic-reoxygenated (HR) cardiomyoblasts with 
and without PJ34. (b) quantitative data. Each bar represents the 
mean ± SEM of five different dot blots and relative densitometric 
quantifications. All signals were quantified by densitometric analy-
sis, and are expressed as ratio of nuclear ADP-ribosylated proteins 
densitometry on histone H1 (loading control) densitometry. (c) Dot 
blot analysis of histone H1: a control for equal protein loading. 
* Significant difference ( p < 0.05) from control, and ° significant 
difference ( p < 0.05) from HR + PJ34.
Figure 3. (a) Mitochondrial activity, assessed by MTT test, in con-
trol (C), hypoxic (H), hypoxic-reoxygenated (HR) cardiomyoblasts 
with and without PJ34. Results were expressed as the percentage of 
MTT reduction, assuming the absorbance of control cells as 100%. 
(b) ATP levels determined by a bioluminescence assay in control 
(C), hypoxic (H), hypoxic-reoxygenated (HR) cardiomyoblasts 
with and without PJ34. Results were expressed as a percentage 
of control values (assumed as 100%). (c) NAD+ levels assayed by 
a method based on its conversion to NADH by alcohol dehydro-
genase in control (C), hypoxic (H), hypoxic-reoxygenated (HR) 
cardiomyoblasts with and without PJ34. Results were expressed 
as a percentage of control values (assumed as 100%). All values 
represent mean ± SEM of five independent experiments. * Signifi-
cant difference ( p < 0.05) from control and ° significant difference 
( p < 0.05) from HR + PJ34.
Table 2. PARP activity a.




4 ± 0.41 4.7 ± 0.45 10.9 ± 1.93**° 4.9 ± 0.50
a PARP activity in control (C), hypoxic (H), hypoxic-reoxygenated 
(HR) cardiomyoblasts with and without PJ34. Unit definition: 1 U 
PARP incorporates 100 pmol poly(ADP) from NAD+ into acid-in-
soluble form in 1 min at 22 °C. Values represent mean ± SEM of five 
independent experiments. **Significant difference ( p < 0.001) from 
control and °significant difference ( p < 0.001) from HR + PJ34.
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Effects on cellular viability, necrosis and apoptosis. Re-
oxygenation for 90 min of hypoxic H9c2 cardiomyoblasts 
markedly and significantly increased (about twofold over 
the control level) the LDH release in the culture medium 
(Fig. 4A), which is considered to account for cell mortal-
ity and, especially, for necrotic cell death. These results are 
consistent with those obtained by the commonly used cell 
viability assay based on trypan blue exclusion (Fig. 4B). 
Under these conditions, however, we also found a signifi-
cant enhancement of oligonucleosomal DNA fragmenta-
tion, a finding that is generally accepted as an hallmark 
of apoptosis (Fig. 5). To assess the caspase dependence 
of this DNA fragmentation pattern, HR cells were treated 
with the caspase inhibitor Z-VAD-fmk: this treatment did 
not produce significant changes, so that DNA fragmenta-
tion may be considered, at least in these conditions, a cas-
pase-independent process. Consistent with these findings, 
our determinations revealed that, in HR cells, cytochrome 
c (an activator of the caspase pathway) was significantly 
released into the cytosol (Fig. 6a), but the levels of both 
the catalytically active form of caspase-3 (Fig. 6b), a 
downstream effector of caspase-dependent apoptosis, 
and those of the typical fragment of PARP-1 (Fig. 7a), 
produced through the proteolytic cleavage of this enzyme 
by caspase-3, did not significantly differ from the control 
values. Thus, it appears unlikely that the cytochrome c/
caspase pathway was involved in the apoptosis of our HR 
cardiomyoblasts. These cells, on the other hand, exhibited 
a significant translocation of AIF (Fig. 7b), as indicated 
by the strong nuclear signal for this factor. PJ34 treat-
ment of HR cardiomyoblasts resulted in several consider-
able changes with respect to the corresponding untreated 
cells: LDH release was drastically decreased and apop-
tosis also appeared to be significantly reduced, as indi-
cated by the differences observed in oligonucleosomal 
DNA fragmentation. Moreover, as for the mechanisms 
potentially involved in the apoptotic processes occurring 
in these conditions, we found that AIF nuclear transloca-
tion was nearly absent, while cytochrome c release into 
the cytosol, caspase-3 activation, and PARP-1 cleavage 
were significantly higher in the PJ34-treated, rather than 
in the untreated, HR cells. DNA fragmentation observed 
in the PJ34-treated HR cardiomyoblasts was significantly 
reduced by Z-VAD-fmk treatment, which suggests a cas-
pase dependence for this process.
To characterize more deeply the rate and the mode of cell 
death during hypoxia-reoxygenation, and the effects of 
PJ34 in this connection, apoptotic, necrotic and living cells 
were differentiated and quantified by flow cytofluorom-
etry (annexin/PI staining). The results of these determina-
tions (Fig. 8) indicate that, after hypoxia-reoxygenation, 
Figure 4 (a) LDH activity, as an index of necrotic death, released 
into the medium in control (C), hypoxic (H), untreated and PJ34-
treated hypoxic-reoxygenated (HR) cardiomyoblasts. LDH activity 
was assessed in the culture medium and in adherent cells (to obtain 
total LDH content) after hypoxia-reoxygenation and in the control 
cells. LDH release was calculated as a percentage of total LDH 
content. (b) Trypan blue exclusion assay. The cellular suspension 
treated with trypan blue solution was counted with a hemocytom-
eter where non-viable cells are stained and viable cells exclude the 
stain. The percentage of viable cells in the different groups was 
determined from cell counts in H or HR cells divided by cell counts 
of controls. Values represent mean ± SEM of five independent ex-
periments. * Significant difference ( p < 0.05) from control, and 
° significant difference ( p < 0.05) from HR + PJ34.
Figure 5. DNA fragmentation, as an index of apoptotic death, in 
control (C), hypoxic (H), hypoxic-reoxygenated (HR) cardiomyo-
blasts with and without PJ34. DNA fragmentation was expressed as 
the enrichment of histone-associated mono- and oligonucleosomes 
released into the cytoplasm by measuring the absorption at 405 nm. 
The enrichment factor is considered to be proportional to the number 
of apoptotic cells present in the population. Each value is the mean 
± SEM of five independent experiments. * Significant difference 
( p < 0.05) from control, ° significant difference ( p < 0.05) from 
HR + PJ34 and # significant difference ( p < 0.05) from HR + PJ34 
without Z-VAD-fmk.
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the living cells were significantly reduced with respect 
to the control level and that both necrosis and apoptosis 
contributed, almost in the same measure, to this effect. 
Compared with the corresponding untreated cells, HR 
cardiomyoblasts subjected to PJ34 treatment exhibited 
a reduction in apoptotic and, even more, in the necrotic 
processes, an effect that may account for the concomitant 
increase that we found in the number of living cells.
Discussion
A first consideration that is suggested by the results of the 
present study regards the effectiveness of our hypoxia/re-
oxygenation treatment to enhance ROS production and 
to induce oxidative stress, the occurrence of which was 
indicated by typical biochemical markers. As for PARP-1 
activity, the low levels detectable in control cells suggest, 
in agreement with previous reports [22], that a baseline 
oxidative DNA damage is occurring within cell nuclei. 
Poly(ADP-ribosyl)ation of nuclear proteins and PARP-
1 activity were unchanged during the hypoxic phase but 
underwent a marked increase after 90 min reoxygen-
ation, consistent with the view that PARP-1 is primarily 
involved in the reperfusion injury. The discrepancy be-
tween the increase in PARP-1 activity (about threefold 
with respect to controls value) and that observed for the 
poly-(ADP ribosyl)ation level of nuclear protein (about 
80% above the control value) may be due to the fact that 
the latter represents the result of two enzymatic activities: 
PARP-1 and poly(ADP- ribose) glycohydrolase (PARG), 
an enzyme that can act with high efficiency poly(ADP-
ribose) immediately upon the initiation of its synthesis; 
furthermore, PARG has a higher specific activity than 
PARP-1, and its catalytic activity rises with the increasing 
length of poly(ADP-ribose) chain [23]. To see whether 
the degree of PARP-1 activation affected the rate and/or 
the mode of death in HR cardiomyoblasts, our determina-
tions were performed in the absence and in the presence 
of PJ34. This belongs to a class of recently synthesized 
bicyclic and tricyclic PARP-1 inhibitors that have proved 
to be much more selective and potent in comparison with 
Figure 6. (a) Western blot analysis of cytosolic cytochrome c in 
control (C), hypoxic (H) and hypoxic-reoxygenated (HR) cells. (A) 
Representative Western blot; (B) quantitative data. All signals were 
quantified by densitometric analysis and are expressed as ratio of 
cytochrome c densitometry on β-tubulin (loading control) densi-
tometry. Each bar represents the mean ± SEM of five different blots 
and relative densitometric quantifications. (C) Western blot analy-
sis of β-tubulin: a control for equal protein loading. (b) Western 
blot analysis of caspase-3 active fragment in control (C), hypoxic 
(H) and hypoxic-reoxygenated (HR) cells. (A) representative im-
munoblot. (B) quantitative data. All signals were quantified by den-
sitometric analysis and are expressed as ratio of caspase-3 active 
fragment densitometry on β-tubulin (loading control) densitometry. 
Each bar represents the mean ± SEM of five different blots and rela-
tive densitometric quantifications. (C) Western blot analysis of β-
tubulin: a control for equal protein loading. * Significant difference 
( p < 0.05) from control and ° significant difference ( p < 0.05) from 
HR + PJ34.
3068       C. Fiorillo et al. PJ34 cardioprotection in hypoxia reoxygenation
the classical substrate analogues such as nicotinamide or 
3-aminobenzamide [24]. These new compounds, devoid 
of inherent antioxidant activity, are characterized by low-
micromolar to mid-nanomolar inhibitory potencies in 
whole-cell-based assays, besides producing relevant ef-
fects when administered to animals in dosing range of 
few milligrams per kilogram of body weight [25]. Owing 
to its high inhibitory power, hydrosolubility and oral bio-
availability, PJ34 appears as one of the most promising 
among the recent PARP-1 inhibitors, especially in view 
of a possible clinical utilization [26, 27].
In this study PJ34, used at a final concentration of 0.5 µM 
(about fivefold the concentration needed to produce a 
50% inhibition in PARP-1 activity tests based on NAD+ 
consumption [28]), strongly reduced not only PARP-1 ac-
tivation but also ROS production and oxidative stress in 
HR cardiomyoblasts, at the same time preserving the an-
tioxidant defenses of these cells. Since PJ34 does not per 
se possess antioxidant activity, a plausible explanation for 
this finding may be that this inhibitor suppresses the abil-
ity of activated PARP-1 to promote mitochondrial dam-
age and dysfunction, and hence a secondary increase in 
ROS generation. In this connection, it has been reported 
that the exposure of cultured cells to oxidative stress 
produces a time- and dose-dependent decrease in mito-
chondrial transmembrane potential (∆Ψm), which is as-
sociated with an increased ROS production, probably due 
to an enhanced univalent leakage of the respiratory chain 
[29]; under these conditions PARP-1 inhibition has been 
found to attenuate both the oxidative stress-induced ∆Ψm 
reduction and the secondary ROS generation [30]. Mi-
tochondrial dysfunction associated with PARP-1 activa-
tion is mainly ascribed to the depletion of NAD+ [31], the 
pool of which is largely compartmentalized within these 
organelles. Some authors [32], however, have suggested 
that molecular signals released from the nucleus of cells 
Figure 7. (a) Western blot analysis of 89 kDa PARP fragment in control (C), hypoxic (H) and hypoxic-reoxygenated (HR) cells. (A) rep-
resentative immunoblot. (B) quantitative data. All signals were quantified by densitometric analysis and are expressed as ratio of 89 kDa 
PARP fragment densitometry on Histone H1 (loading control) densitometry. Each bar represents the mean value ± SEM of five different 
blots and relative densitometric quantifications. (C) Western blot analysis of histone-H1: a control for equal protein loading. (b) Western 
blot analysis of nuclear AIF in control (C), hypoxic (H) and hypoxic-reoxygenated (HR) cells. (A) representative Western blot; (B) quan-
titative data. All signals were quantified by densitometric analysis and are expressed as ratio of AIF densitometry on histone-H1 (loading 
control) densitometry. Each bar represents the mean value ± SEM of five different blots and relative densitometric quantifications. (c) 
Western blot analysis of histone-H1: a control for equal protein loading. * Significant difference ( p < 0.05) from control and ° significant 
difference ( p < 0.05) from HR + PJ34.
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undergoing massive poly(ADP-ribosyl)ation can rapidly 
modify mitochondrial functioning; a possible candidate 
messenger for these effects could be free ADP-ribose, the 
main degradation product of poly(ADP-ribose). It should 
also be noted that, as recently reported by Halmosi et al. 
[33], the compounds of the PJ34 family, besides their 
primary effect of inhibiting PARP-1, seem to have addi-
tional mitochondrial targets and to protect the respiratory 
complexes from ROS-induced inactivation. This might be 
a further mechanism accounting for a reduced secondary 
ROS generation by mitochondria, thus the attenuation of 
oxidative stress induced by PJ34 treatment. Whatever the 
case, all the above-proposed mechanisms implicate an ac-
tion at the mitochondrial level that is consistent with our 
data showing a significant improvement of mitochondrial 
respiration owing to the treatment with this PARP-1 in-
hibitor.
As for the effects of PARP-1 activity on the rate and 
the mode of cell death, the present results suggest that 
both necrosis and apoptosis account for the consider-
able mortality of HR cardiomyoblasts not subjected to 
PARP-1 inhibition, as clearly highlighted by cytofluoro-
metric quantification of live, necrotic and apoptotic cells 
(Fig. 8). Furthermore, the marked translocation of AIF 
to the nuclear fraction that we found in these cells, in 
agreement with previous reports [34], suggests that this 
factor is probably responsible for their apoptotic death. 
The release of both cytochrome c and AIF (effects that 
may be ascribed to the mitochondrial dysfunction pro-
duced by PARP-1 activation through the mechanisms dis-
cussed above) was evident when HR cardiomyoblasts did 
not undergo treatment with PJ34; under these conditions, 
however, cytochrome c appeared unable to activate the 
corresponding apoptotic pathway. As a possible explana-
tion for this finding we propose that energy loss due to a 
strong PARP-1 activation prevents the energy consuming 
cytochrome c/caspase-dependent apoptosis, but allows 
the development of a (relatively) energy inexpensive pro-
cess such as the AIF-dependent apoptotic pathway.
This interpretation implies that the oligonucleosomal 
DNA fragmentation that we found in HR cells represents 
a caspase-independent and AIF-dependent process. We 
are aware that this does not agree with most published 
literature that generally depicts AIF as an apoptotic effec-
tor protein inducing chromatin condensation and large-
scale DNA fragmentation [35]. In a recent report, how-
ever, Yuste et al. [36] have challenged this view, providing 
evidence that AIF, which lacks intrinsic nuclease activity, 
can affect chromatin condensation but does not control 
the pattern of DNA degradation. The same authors pro-
pose that high or low molecular weight DNA fragmen-
tation depends on the activity of endogenous nucleases, 
notably (at least in their model) on the combined effect 
of caspase-activated DNase (CAD) and of its inhibitor 
Figure 8. Flow cytometric analysis of apoptosis and necrosis in H9c2 cardiomyoblasts labeled with FITC-annexin V–PI. Dot plot shows 
three populations: Q2 = necrotic cells, Q3 = living cells and Q4 = apoptotic cells in control, in hypoxic cells (H) and in hypoxic-re-
oxygenated (HR) cells with and without PJ34 (A). These data are represented in histograms showing percentages ± SEM (five different 
experiments performed) of living (B), apoptotic and necrotic cells (C): * Significant difference ( p < 0.05) from control and ° Significant 
difference ( p < 0.05) from HR+PJ34 (B).
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(ICAD). In our experimental conditions, owing to the 
established caspase independence of the observed DNA 
fragmentation, we should invoke the involvement of other 
DNases. A stimulating, although at present only specula-
tive, hypothesis may be that mitochondrial dysfunction, 
besides AIF, can also induce the release of endonuclease 
G, a mitochondrion-specific enzyme that during apop-
tosis translocates to the nucleus, inducing nucleosomal 
DNA fragmentation independently of caspases [37, 38].
In HR cardiomyoblasts subjected to PJ34 treatment, the 
observed changes in the rates of LDH leakage, in the try-
pan blue exclusion assay, in oligonucleosomal DNA frag-
mentation and in the cytofluorometric analysis indicate 
that PARP-1 inhibition can induce a significant decrease 
in cell mortality, mainly due to a reduction of necrotic 
death but also to an attenuation of the apoptotic processes; 
these, however, did not appear to proceed through AIF, 
whose nuclear translocation was undetectable, but through 
the caspase-dependent pathway, as suggested by the fact 
that, in this case, the mitochondrial release of cytochrome 
c was associated with caspase-3 activation and with the 
typical PARP-1 cleavage. Probably, energy saving due to 
PARP-1 inhibition allowed the development of the ATP-
requiring caspase-mediated apoptosis, while, as regards 
to the relationships between PARP-1 activity and the re-
lease of cytochrome c and AIF, these may be tentatively 
attributed to the different molecular size of these proteins 
and to their different organization in the mitochondrial 
structure [39]. As proposed in a recent report by Goldstein 
et al. [40], it is possible that, because of its lower molecu-
lar weight and its weaker binding to mitochondrial inner 
membrane, cytochrome c is more easily released, thus 
mild mitochondrial changes induced by moderate levels 
of PARP-1 activation might be sufficient to trigger the 
release of cytochrome c but not that of AIF.
In conclusion, the data reported here support the view 
that PARP-1 is an important regulator of cell survival and 
death in the myocardial injury due to post-hypoxic re-
oxygenation. Our results suggest that changes in the level 
of energy depletion and in the mitochondrial release of 
cell death factors, owing to the degree of PARP-1 activa-
tion, may result in varying combination of necrosis and 
apoptosis. From this point of view PARP-1 inhibition by 
PJ34 appears to produce beneficial effects, principally 
by reducing the overall mortality of the tested cells. This 
encourages us to undertake further studies aimed at prob-
ing the potentialities of this class of PARP-1 inhibitors 
more deeply, so as to optimize, if necessary even through 
additional treatments, their protective effect against myo-
cardial reperfusion injury.
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